Silencing the MET oncogene leads to regression of experimental tumors and metastases

S. Corso, C. Migliore, E. Ghiso, G. De Rosa, P. M. Comoglio, S. Giordano

Research output: Contribution to journalArticlepeer-review


In spite of the established knowledge of the genetic alterations responsible for cancer onset, the genes promoting and maintaining the invasive/metastatic phenotype are still elusive. The MET proto-oncogene, encoding the tyrosine kinase receptor for hepatocyte growth factor (HGF), senses unfavorable micro-environmental conditions and drives cell invasion and metastasis. MET overexpression, often induced by tumor hypoxia, leads to constitutive activation of the receptor and correlates with poor prognosis. To establish the role of MET in different phases of tumor progression, we developed an inducible lentiviral delivery system of RNA interference. Silencing the endogenous MET gene, overexpressed in tumor cells, resulted in (i) impairment of the execution of the full invasive growth program in vitro, (ii) lack of tumor growth and (iii) decreased generation of experimental metastases in vivo. Notably, silencing MET in already established metastases led to their almost complete regression. This indicates that persistent expression of the MET oncogene is mandatory until the advanced phases of cancer progression.

Original languageEnglish
Pages (from-to)684-693
Number of pages10
Issue number5
Publication statusPublished - Jan 24 2008


  • Growth factor receptor
  • Invasion
  • Metastasis
  • Tumor progression

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics


Dive into the research topics of 'Silencing the MET oncogene leads to regression of experimental tumors and metastases'. Together they form a unique fingerprint.

Cite this